Zimmer Biomet Expects Strong Q2 Earnings, Raises Guidance on Robust Performance and Strategic Acquisitions

Zimmer Biomet Holdings reported a 2.8% increase in sales for Q2 2025, driven by strong performance in the US Hips and US Knees segments. The company raised its 2025 adjusted earnings per share guidance to $8.10-$8.30 and announced the acquisition of Monogram Technologies to enhance its robotic capabilities. However, Zimmer Biomet faced challenges including international order delays, tariff impacts, and decreased operating margins.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) reported its second quarter (Q2) 2025 financial results, showcasing a robust performance driven by significant growth in the U.S. Hips and Knees segments. The company reported net sales of $2.077 billion, marking a 7.0% increase on a reported basis, 5.4% on a constant currency basis, and 2.8% on an organic constant currency basis [1].

The company's adjusted diluted earnings per share (EPS) for Q2 2025 were $2.07, representing a 3.0% increase over the previous year. Zimmer Biomet has also tightened its full-year 2025 financial guidance, projecting reported, constant currency, and organic constant currency revenue growth of 6.7% to 7.7%, 6.2% to 7.2%, and 3.5% to 4.5%, respectively. The adjusted EPS financial guidance for 2025 has been raised to $8.10 to $8.30 [1].

Notable highlights include the company's acquisition of Monogram Technologies, an AI-driven robotics company, to expand its orthopedic robotics and navigation technologies. This acquisition aims to create a more flexible and comprehensive suite of robotic solutions to meet surgeons' needs. Additionally, Zimmer Biomet signed a strategic partnership with Getinge to distribute its operating room capital products to ambulatory surgery center customers [1].

However, the company faced several challenges during the quarter, including international order delays, tariff impacts, and decreased operating margins. These challenges have impacted the company's performance and are reflected in the adjusted guidance for 2025 [1].

Zimmer Biomet's strong performance in the U.S. Hips and Knees segments, coupled with the acquisition of Monogram Technologies, positions the company for continued growth in the coming quarters. The company's ability to navigate the challenges of international order delays and tariff impacts will be crucial for maintaining its growth trajectory.

References:
[1] https://www.prnewswire.com/news-releases/zimmer-biomet-announces-second-quarter-2025-financial-results-302523852.html